The evolution of multi-omics approaches and large-scale sequencing has significantly advanced target discovery, particularly for genes implicated in currently incurable diseases. Technologies such as CRISPR and RNAi facilitate genome-wide perturbation studies, yet they often fall short in providing functional characterization or insights into druggable pockets of target genes. This gap highlights the need for innovative solutions in early drug discovery.
Introducing SITESEEKER, a cutting-edge target discovery platform that leverages hyper-diverse libraries of mini-proteins, or PROTEINi®, to identify novel druggable pockets on target proteins. By employing advanced computational tools and high-throughput screening in disease-relevant cell models, SITESEEKER not only enhances target identification but also maps intricate protein interaction networks, revealing uncharacterized biological pathways. Such insights are pivotal for developing precise and effective targeted interventions.
As SITESEEKER expands into targeted protein degradation (TPD), its versatility in therapeutic areas like oncology and immunology becomes apparent. The platform’s ability to identify novel E3 ligases can mitigate safety and resistance issues associated with existing therapies. With the rapid evolution of TPD discovery, SITESEEKER stands at the forefront, promising to unlock new therapeutic avenues for previously undruggable targets.
